The CVD-REAL study

CVD-REAL is a multinational, observational cohort study in patients with type 2 diabetes mellitus initiating treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor versus another glucose-lowering drug. This study compares the risk of clinically relevant cardiovascular and renal outcomes and all-cause mortality in patients who are new users of SGLT-2 inhibitors with the risk in those who are new users of other glucose-lowering drugs1. CVD-REAL has collected data from approximately 4 million patients, from 14 countries across four major world regions.

CVD-REAL IS NOW COMPLETE

Published findings from CVD-REAL can be found at the following links:

CVD-REAL 1

CVD-REAL 2

CVD-REAL 3

Study map infographic

The CVD-REAL study

CVD-REAL is a multinational, retrospective, observational cohort study in patients with type 2 diabetes mellitus who are initiating treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor or another glucose-lowering drug. This study will compare the risk of hospitalization for heart failure and all-cause mortality in patients who are new users of SGLT-2 inhibitors with the risk in those who are new users of other glucose-lowering drugs. CVD-REAL is aiming to include data from approximately 1.4 million patients overall, from at least six countries.

 

Get involved

Do you work for a large institution or a database provider? Does the database include patients with type 2 diabetes mellitus?

 

Then you may be eligible to get involved in the CVD-REAL study!

 

Contact the CVD-REAL study team today and get involved!